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Abstract
Background
Owing toGiven the high costs of drugs to treat multi-drug resistant tuberculosis (MDR-TB),
the Green Light Committee (GLC) initiative enables TB programs to procure quality-assured
drugs at reduced prices. Despite price reductions, internationally quality assured (IQA)
drugs can be more expensive than locally procured drugs. There is little evidence to inform
decision-makers about whether IQA drugs are more effective than local drugs. This is the
first study to compare outcomes between MDR-TB patients treated using IQA, and locally
procured drugs in the same hospitals during the same time period.
Methods/Findings
A retrospective cohort study was conducted in three hospitals across Pakistan. Data on
baseline characteristics and treatment outcomes during the first six months of treatment
were extracted from hospital records of adult culture-positive pulmonary MDR-TB patients
starting treatment between January 2011 and June 2012. Two cohorts were defined: pa-
tients receiving IQA drugs, and patients receiving locally procured non-IQA drugs. Data
were analysed using Kaplan-Meier curves and Cox proportional hazards regression. The
primary outcome compared between cohorts was time to culture conversion. Of 231 pa-
tients, 90 were in the IQA and 141 in the non-IQA cohorts. Baseline characteristics were
similar except for higher frequency of quinolone resistance in the IQA cohort. Overall, 193
patients (84%) culture converted. Culture conversion was not faster in the IQA cohort; the
median time was 81 and 68 days in the IQA and non-IQA cohorts, respectively. Unadjusted
and adjusted hazard ratios for culture conversion in IQA verses non-IQA cohorts were 0.82
(95%-CI, 0.62-1.10) and 0.95 (95%-CI, 0.66-1.36) respectively.
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Conclusions
Use of good quality, locally procured drugs can be effective in treating MDR-TB, may in-
volve lower costs than using IQA drugs and could strengthen developing country drug quali-
ty assurance systems. This may be a suitable alternative in lieu of or whilst awaiting arrival
of internationally procured medicines.
Introduction
Multi-drug resistant TB (MDR-TB), which is caused by strains ofMycobacterium tuberculosis
resistant to both isoniazid and rifampicin, poses several challenges for National Tuberculosis
Programs (NTPs). Expensive and sophisticated diagnostic methods are needed to confirm
MDR-TB cases and effective treatment requires patients to take costly second-line anti-tuber-
culosis drugs for more than 18 months. Furthermore, the number of MDR-TB cases notified to
NTPs in high burden countries is rising every year and is expected to keep growing. While
94,000 MDR-TB cases were diagnosed in 2012, reports suggest that less than 25% of the people
who are estimated to have MDR-TB were identified[1].
A major barrier to provision of timely and effective treatment by NTPs is the high cost of
quality-assured second line drugs (SLDs). In order to promote access to and rational use of
SLDs for the treatment of MDR-TB, the WHO formed a multi-institutional partnership called
the Green Light Committee (GLC)[2,3]. The GLC initiative enables approved MDR-TB pro-
grams to access high quality second-line drugs at reduced prices through the Global Drug
Facility (GDF)[4]. The GDF has a quality assurance system in place to ensure that all drugs
supplied to GLC-approved projects are safe, effective and appropriately labelled. Price reduc-
tions are achieved through negotiations with pharmaceutical companies and pooled procure-
ment of drugs generating economies of scale. Despite the subsidies, procuring drugs
internationally through the GDF can be more expensive and logistically challenging for already
over-burdened NTPs than procuring drugs from the local market. It is estimated that the addi-
tional costs associated with international transport, customs clearance and further local distri-
bution results in internationally quality assured (IQA) drugs being 15–20% more expensive
than locally procured drugs. Concerns about use of locally procured drugs, on the other hand,
relate to quality and effectiveness compared to IQA drugs. In Pakistan, pharmaceutical drugs
are regulated under The Drugs Act 1976; licensed manufacturers of drugs are to comply with
local Good Manufacturing Practices (GMP) guidelines which outline manufacturing, storage,
quality control assays and documentation requirements. However there are limited resources
to monitor drug quality once a manufacturer has been granted a licence, and variations in qual-
ity may occur after a drug has been licensed.
Evidence from existing literature on patient benefit through use of IQA drugs is limited. An
analysis of the first five projects approved by the GLC, involving data from 1768 MDR-TB pa-
tients reported treatment success in 65%, default in 14%, failure in 7% and death rates of 11%
[5]. In comparison, a meta-analysis of treatment outcomes from non-GLC approved programs,
which included data from 21 countries reported similar treatment outcomes: 62% of patients
had successful outcomes, while 13% defaulted, 8% failed therapy and 11% died[6]. A crude
comparison therefore does not suggest better treatment outcomes among patients taking IQA
drugs versus non-IQA drugs. To our knowledge, however, there are no studies which directly
compare outcomes between patients on IQA and non-IQA approved treatment in the same
settings during the same time period.
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Pakistan ranks fifth in terms of global MDR-TB burden[1]. In 2010, the Pakistan NTP initi-
ated a pilot program though which the country’s main MDR-TB hospitals were provided IQA
drugs and social support, in the form of monthly basic food rations and transport reimburse-
ment, for a fixed number of patients each year. IQA drugs for 235, 500 and 882 patients were
obtained in the years 2010, 2011 and 2012 respectively. The drugs were distributed between the
main public sector hospitals managing MDR-TB patients. When batches of IQA drugs were re-
ceived by hospitals, confirmed MDR-TB patients waiting to initiate treatment and any cases di-
agnosed after drugs had been received were started on a course of IQA drugs. In some cases,
hospitals would switch a patient who had recently started a course of non-IQA drugs to IQA
drugs. When IQA drugs had run out at a hospital, newly diagnosed patients were treated using
locally available drugs until IQA drugs became available again. There was no cost to the patient
for treatment when either IQA or non-IQA drugs were used. For procurement of locally avail-
able drugs, large hospitals, such as the Ojha Institute of Chest Diseases (OICD) in Karachi, fol-
low a system to ensure drug quality which involves selecting manufactures with good
credentials, reviewing manufacturers’ literature on drug characteristics (bioavailability etc.),
and conducting independent chemical analyses where possible.
The objective of this study was to compare response to treatment in patients treated using
IQA drugs through the GLC initiative with those treated according to standard local protocols
using non-IQA drugs in the same hospitals during the same time period. The question being
addressed is whether IQA drugs are more effective in treating MDR-TB than locally procured
drugs.
Methods
Setting and Participants
A retrospective cohort study was conducted in three hospitals in different regions of Pakistan:
OICD (Karachi), Leprosy Hospital (Rawalpindi) and Institute of Chest Diseases Kotri (Hydera-
bad). Hospitals were included in the study if they were treating MDR-TB patients using both
IQA and non-IQA drugs simultaneously. Hospitals that were treating patients with exclusively
IQA or non-IQA drugs during the study period were not included as patient populations
may differ.
Culture-positive adults who were enrolled on to treatment for pulmonary MDR-TB at the
study hospitals between January 2011 and June 2012 were included in the study. Exclusion cri-
teria were: age under 15 years, only extra-pulmonary TB diagnosed, culture positive at diagno-
sis but negative/missing culture result at treatment initiation and default immediately before
initiating treatment. Patients who had received less than 30 days of non-IQA drugs before
starting on IQA drugs for their entire treatment were included in the study and classified as re-
ceiving IQA drugs. Any patients who had been switched from non-IQA to IQA drugs more
30 days after treatment initiation were excluded from the study.
All patients received free individualized treatment regimens at the study hospitals. Sputum
smears and cultures were performed at diagnosis, initiation of treatment and at monthly fol-
low-up visits over the course of treatment. Patients were followed up for six months after
treatment initiation.
Definitions of outcomes and explanatory variables
Time to conversion of sputum mycobacterial cultures, which is recognized as the most impor-
tant interim indicator of the efficacy of anti-TB treatment for MDR disease[7,8], was the pri-
mary outcome used to compare IQA and non-IQA approved treatment. Culture conversion
was defined as two consecutive negative sputum cultures at least one month apart. Time to
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culture conversion was defined as the time between treatment initiation and the first of the two
negative cultures. If culture conversion had not occurred, observations were censored at the
earliest of death, default or at six months post treatment initiation.
Secondary outcomes were time to sputum smear conversion, weight gain six months after
treatment initiation and occurrence of drug-related side effects during the first six months after
treatment initiation. Time to sputum smear conversion was defined as the time between treat-
ment initiation and the first of two negative sputum smear microscopy results. This analysis re-
stricted to patients who had a positive sputum smear result at the time of treatment initiation.
If a patient’s sputum remained smear-positive, observations were censored as previously
described.
Among the explanatory variables, the initial drug regimen was defined as the number of
drugs prescribed in the first month of treatment. Drugs that were removed from the regimen
within 30 days of initiation were not counted. Drugs to which patient isolates is sensitive was
defined as drugs given to the patient for at least one month to which there was no resistance de-
tected during drug sensitivity testing. Period of treatment initiation was classified into three
categories based on the calendar month during which a patient was started on treatment: Janu-
ary—June 2011, July – December 2011 and January 2012 – June 2012. Treatment initiation
delay was defined as the time between a positive diagnostic culture for MDR-TB and treatment
initiation. Previous first and second line TB treatments were defined as the most recent first
and second line treatments received prior to MDR-TB treatment initiation at the study site, re-
spectively. Initial sputum microscopy grading results were taken for the specimen submitted at
the time of treatment initiation or within two weeks of treatment initiation if no sputum mi-
croscopy was conducted on the day of treatment initiation.
Data sources
Data on patients’ baseline characteristics, TB treatment history, current disease severity and
treatment progress indicators were extracted from hospital records for a period of six months
following treatment initiation and directly entered into a database. Individual patient data were
checked by a data supervisor on a weekly basis, and any data entry errors identified were cor-
rected by referring to the hospital records. Two cohorts of patients were defined: those who re-
ceived IQA drugs and associated social support through the GLC initiative (IQA cohort) and
those who received locally procured drugs (non-IQA cohort).
Study size
The sample size was determined by the number of MDR patients being diagnosed and treated
using IQA or non-IQA drugs during the study period; a power calculation was conducted at
the beginning of the study. Using NTP records it was estimated that 109 patients had initiated
treatment on IQA drugs and
200 patients had initiated treatment on non-IQA drugs at the study hospitals between Janu-
ary 2011 and June 2012. It was expected that 20% of patients in the non-IQA cohort will cul-
ture convert by 3 months post treatment initiation, based on a previous study conducted in
Pakistan[8]. We estimated that a programmatically important difference between the cohorts
would be 15% (ie. 35% of patients in the IQA cohort culture convert by 3 months post treat-
ment initiation). Based on these data we estimated the study will have a power of 82% with a
two-sided type I error of 5%.
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Statistical analysis
Baseline characteristics of cohorts were compared using chi—square test for categorical vari-
ables and t-test for continuous variables. Cox proportional hazards regression was used to as-
sess the effect of IQA versus non-IQA treatment on time to sputum smear and culture
conversion. Unadjusted and adjusted hazard ratios of sputum smear and culture conversion in
IQA and non-IQA cohorts were calculated. Potential confounders identified a priori based on
literature were used in the adjusted model. The proportionality assumption of the Cox model
was assessed graphically. Kaplan-Meier curves were used to show time to sputum smear and
culture conversion by IQA and non-IQA cohorts. Weight gain between cohorts was compared
using multiple linear regression to control for potential confounders. Frequency of reported
side-effects was compared using the z-test. All analyses were conducted using Stata/ IC
11.0 (Stata Corp, College Station, TX, USA).
Ethics Statement
This study received ethical approval from the Pakistan Medical Research Council and the Lon-
don School of Hygiene and Tropical Medicine. Since pre-existing secondary patient data was
analysed and there was no contact with patients during data collection, the institutional review
boards did not require informed consent to be taken. All data abstracted from existing patient
records were anonymised.
Results
Of 314 patients listed in the MDR treatment registers at the study hospitals during the study
period, 83 were excluded because they were either not resistant to both isonaizid and rifampi-
cin, were culture-positive at diagnosis but culture-negative by the time of treatment initiation
or defaulted immediately before initiating treatment. Thus 231 patients were included in the
study and of these 90 were in the IQA cohort and 141 were in the non-IQA cohort.
Patient baseline characteristics were generally similar across cohorts as was TB treatment
history (Table 1). The median age was 32 and 31 years and median weight was 42 and 40 kilo-
grams in the IQA and non-IQA cohorts, respectively. Female patients comprised 41% and 48%
of the IQA and non-IQA cohorts respectively. Overall, 58% of patients were resistant to five
first-line drugs and 5% were resistant to injectable second line drugs. Resistance to quinolones
however was more frequent in the IQA cohort (60% vs 43%). There were no notable differences
between cohorts in the overall number of drugs or regimens prescribed apart from the choice
of aminoglycoside antibiotic used; Kanamycin was used more frequently in the non-IQA co-
hort (70% in non-IQA cohort vs 11% in IQA cohort, p<0.01) and Amikacin was used more
frequently in the IQA cohort (28% in non-IQA cohort vs 79% in IQA cohort, p<0.01). The
treatment initiation delay of 54 days was similar in the two cohorts and the mean number of
drugs in the initial regimen to which patient isolates were susceptible was 4.5 in the IQA cohort
and 4.6 in the non-IQA cohort.
One hundred and ninety-three patients (84%) culture converted within six months of treat-
ment initiation. Median time to culture conversion was 81 days in the IQA cohort and 68 days
in the non-IQA cohort (Table 2 and Fig 1). The unadjusted hazard ratio for culture conversion
in the IQA verses non-IQA cohort was 0.82 (95% CI, 0.62–1.10; p = 0.19). After adjusting for
potential confounding factors (age, gender, initial weight, previous first or second line drug
use, sputum microscopy result at treatment initiation, resistance to first and second line drugs,
number of drugs received to which the patient isolate was sensitive, period of treatment initia-
tion, hospital at which patients received MDR-TB treatment and treatment initiation delay),
the hazard ratio was 0.95 (95% CI, 0.66–1.36; p = 0.78).
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Of the 231 culture-positive patients included in the study, 217 (94%) were also smear-posi-
tive and were included in the time to smear conversion analysis. Overall, 152 patients (70%)
smear converted during the study period. Eighty-five percent (71/84) of patients in the IQA co-
hort and 61% (81/133) patients in the non-IQA cohort smear-converted within six months of
treatment initiation. Unlike time to culture conversion, time to smear conversion was shorter
in the IQA cohort (Median 70 days vs 132 days, Fig 2; adjusted hazard ratio, 2.34 [95% CI
1.58 – 3.46, p<0.01]).
To further understand the differences observed between cohorts in time to smear conver-
sion, exploratory analyses were conducted. Comparing smear and culture results from the
Table 1. Patient characteristics at baseline by cohort (n = 231).
IQA drugs
(n = 90)
Non-IQA drugs
(n = 141)
p-
value
Female sex; n (%) 37(41) 67(48) 0.34
Age in years; Mean (Range) 32(16–65) 31(16–70) 0.39
Weight in kg at treatment initiation; Median(IQR) 42(35–48) 40(36–46) 0.81
Hospital at which patients received MDR-TB treatment; n
(%)
OICD (Karachi) 66(73) 103(73) <0.01
ICDK (Hyderabad) 15(17) 37(26)
LHR (Rawalpindi) 9(10) 1(1)
Previous ﬁrst-line treatment; n(%)
None 0(0) 1(0.7) 0.72
Category I 26(29) 35(25)
Category II 64(71) 105(75)
Previous second-line treatment; n(%)
Received 8(9) 9(6) 0.61
Not Received 82(91) 132(94)
Initial sputum microscopy result*; n(%)
Positive 84(93) 133(94) 0.41
Negative 1(1) 4(3)
Number of ﬁrst line drugs to which patient is resistant
additional to isoniazid and rifampicin; n(%)
No drugs 0(0) 7(5) 0.13
1 drug 12(13) 13(9)
2 drugs 26(29) 40(28)
3 drugs 52(58) 81(57)
Resistance to injectable drugs 4(4) 8(6) 0.68
Resistance to quinolones 54(60) 61(43) 0.01
Resistance to any of PAS/Eto/Cs 10(11) 14(10) 0.77
XDR-TB patients 4(4) 4(3) 0.52
Treatment initiation delay in days; Median(IQR) 54(10–66) 54(4–75) 0.28
Initial drug regimen
Drugs received for at least one month; Mean(range) 5.7(4–8) 5.7(3–7) 0.94
Drugs received for at least one month to which the
patient isolate is sensitive; Mean(range)
4.5(0–6) 4.6(3–6) 0.14
IQA = Internationally quality assured; IQR = interquartile range; PAS = Para aminosalicylic acid /
Eto = Ethionamide / Cs = Cycloserine
*9 patients had no sputum smear result within 2 weeks of treatment initiation
doi:10.1371/journal.pone.0126099.t001
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same specimen we found that in the IQA cohort 21% (19/90) of patients had culture positive
and smear negative result compared with 49% (69/141) in the non-IQA cohort. Overall 74% of
the discordant results had a scanty positive smear-microscopy grading (52% and 80% in the
IQA and non-IQA cohorts, respectively). Culture-negative, smear-positive results were not
found to cluster at a particular hospital or time period.
Data on weight at six months post treatment initiation was available for 84% (76/90) and
79% (112/141) of patients in the IQA and non-IQA cohorts. Median weight after six months of
treatment was 44 kg and 45 kg in the IQA and non-IQA cohorts respectively. Weight gain in
the IQA cohort was lower than that in non-IQA cohort even after adjustment for same factors
described previously (adjusted difference in weight was 1.97 kg, 95% CI 0.47 kg to 3.48 kg;
p = 0.01). The proportion of patients who experienced drug-related side-effects was 38% and
30% (p = 0.21) in the IQA and non-IQA cohorts respectively.
Discussion
Results of this study indicate that there was very little difference in the primary outcome, time
to culture conversion, between IQA and non-IQA cohorts. Good culture conversion rates were
achieved using both types of drugs; more than 75% of patients treated using IQA or non-IQA
drugs had sputum cultures negative for mycobacterial growth by the time they had completed
four months of treatment. Median times to culture conversion in this study were substantially
shorter than the 196 days previously reported in a single-centre study in Pakistan for patients
Table 2. Treatment success indicators by cohort (n = 231).
IQA drugs
(n = 90)
Non-IQA drugs
(n = 141)
p-
value
Patients experiencing culture conversion; n(%) 74(82) 119(84) 0.66
Time to culture conversion in days; Median (IQR) 81(51–122) 68(41–119) 0.18
Cumulative probability of culture conversion at:
60 days; % (95% CI) 33(24–44) 44(36–52) -
90 days; % (95% CI) 58(48–68) 65(57–73) -
180 days; % (95% CI) 84(75–91) 90(84–94) -
Patients experiencing sputum-smear conversion*; n
(%)
71(85) 81(61) <0.01
Time to sputum-smear conversion in days; Median
(IQR)
70(44–121) 132(60–182.5**) <0.01
Cumulative probability of sputum smear conversion at:
60 days; % (95% CI) 45(35–56) 25(19–34) -
90 days; % (95% CI) 65(54–75) 35(27–44) -
180 days; % (95% CI) 88(80–94) 65(56–73) -
Weight at 180 days in kilograms; Median(IQR)† 44 (37–50) 45 (39–51) -
Patients experiencing any side-effects; n(%) 34(38) 42(30) 0.21
Patients that defaulted or died within 6 months of
initiating treatment; n(%)
11(12) 16(11) 0.84
CI = Conﬁdence Interval, IQA = Internationally quality assured, IQR = Interquartile range
*Expressed as a percentage of patients who were smear-positive at treatment initiation (84 in the GLC
group and 133 in the non-GLC group)
** Observations censored after 6 months (182.5 days); 66% converted by 6 months
† Data on weight gain at 6 months post treatment initiation available for 188 patients
doi:10.1371/journal.pone.0126099.t002
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on non-IQA drugs[8]. However, the median time to culture conversion in our study was in line
with data previously reported from Latvia[7], Tanzania[9] and China[10].
An analysis of other treatment success indicators showed that patients in the IQA cohort
did not experience greater weight gain (if anything slightly lesser weight gain) despite provision
of food baskets to patients through the GLC program. Provision of food baskets may have an
impact on adherence or weight gain later in treatment (ie. one year post treatment initiation);
further studies to evaluate the strategy of providing nutritional support are required to draw
conclusions. The frequency of self-reported side-effects did not differ between cohorts
(p = 0.2). These clinical data are consistent with the culture outcome data of similar responses
by IQA and non-IQA cohorts.
There was, however, strong evidence of faster time to smear-conversion in the IQA cohort;
on average, patients on IQA drugs became negative on smear-microscopy almost two months
before patients on non-IQA drugs. The same laboratories processed all samples at each site,
laboratory technicians were unaware of whether patients were receiving IQA or non-IQA
drugs, and there was no evidence of issues with the quality of laboratory results. The only dif-
ference in drug regimens between cohorts was in the choice of aminoglycoside antibiotic used
(Kanamycin versus Amikacin), which should not cause differences in smear-conversion. Since
the majority of smear-positive, culture-negative specimens were scanty positive, it is possible
Fig 1. Kaplan-Meier curve showing time to culture conversion by cohort (n = 231).
doi:10.1371/journal.pone.0126099.g001
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that non-viable bacteria may have been detected on these specimens. The presence of smear-
positive, culture-negative results has been reported in other studies[11,12], but it is not clear
why this phenomenon was more frequent in non-IQA cohort in the study. The apparent dis-
connect between smear and culture conversion between the two patient cohorts remains unex-
plained and warrants further investigation in other settings.
The challenge of diagnosing and managing increasing numbers of MDR TB patients is forc-
ing NTPs in high burden countries to make difficult choices on resource allocation and pro-
gram planning. With the wide-spread introduction of new diagnostics such as the Xpert MTB/
RIF system, it is expected that there will be increasing numbers of newly diagnosed MDR-pa-
tients waiting to be put on treatment in high burden countries, and many countries are now re-
porting such “waiting lists”. A major decision that programs need to make is whether to wait to
receive IQA drugs or to use lower cost drugs that are available locally. Until now evidence on
whether there is a benefit to patients from being treated though IQA drugs has been lacking.
This study is the first to directly compare response to treatment in IQA and non-IQA patient
cohorts undergoing treatment at the same hospitals during the same time period, and to find
no evidence of a faster time to culture conversion in patients treated using IQA drugs.
It must be considered that this was a non-randomized study and that the distribution of un-
identified confounding factors may have been different across cohorts. Apart from higher fluo-
roquinolone resistance in GLC patients, which was adjusted for when calculating adjusted
Fig 2. Kaplan-Meier curve showing time to smear conversion by cohort (n = 231).
doi:10.1371/journal.pone.0126099.g002
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hazards ratios, there was no major difference across cohorts in the baseline variables we stud-
ied. However, there may be other confounders on which we did not collect data. As our follow-
up period ended 6 months from the start of treatment, we were able to compare culture conver-
sion between cohorts but were not able to assess overall treatment success rates and recurrence
rates. We believe that evidence from this first cohort study comparing IQA and non-IQA
drugs warrants a study with a longer follow-up period and, based on the evidence generated,
an assessment of the costs and benefits of using internationally procured drugs for MDR-TB
treatment.
An important factor to consider when interpreting our findings is that the quality of local
drugs used in study hospitals was checked according to hospitals’ own guidelines. We recognize
that ‘locally procured drugs’ encompasses a range of products which can include counterfeit
and substandard drugs[13], and that the drugs used in study hospitals may not be representa-
tive of all second-line antibiotics available on the local market in Pakistan or in other countries.
Nevertheless, results from this study indicate that use of good quality, locally procured drugs
results in a similar time to culture conversion as use of IQA drugs.
In order to ensure that patients are receiving good quality drugs, NTPs and large hospitals
may need to invest in drug quality assurance systems if drugs are being procured locally. The
costs and workload involved in quality assurance would need to be compared with that of in-
ternational procurement and local distribution. An advantage of local procurement and quality
testing would be to encourage growth of the local pharmaceutical industry and to exert pres-
sure on manufacturers to abide by quality standards. Furthermore, if there is sufficient evi-
dence that good quality local drugs are no less effective than internationally procured drugs, it
may be unethical to delay initiation of treatment until international drugs are available in
country.
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